Influenza Vaccine Trial
The goal: a universal flu vaccine
The enrollment of new participants for this study has already been completed (update as of November 13, 2025).
We kindly ask for your understanding and thank you for your interest!
If you are generally interested in participating in our clinical studies, we would be happy if you register without obligation.
Influenza (flu) is an infectious disease caused by influenza viruses. Every year, many millions of people around the world become infected. Older adults, children, and individuals with weakened immune systems are particularly at risk. The flu is also the most common infectious disease contracted while traveling – even though there is a vaccine available.
Since flu viruses constantly change, conventional flu vaccines need to be updated regularly. This study is investigating a new vaccine designed to provide reliable protection even against new virus variants. Its effectiveness is being tested in a placebo-controlled trial, meaning one group receives the actual vaccine while the other receives a placebo.
Study Overview
Investigating the effectiveness and safety of a novel influenza vaccine (Phase II)
At least 2 study visits and 2 follow-up calls over a maximum of 10 months
Additional visits if cold symptoms occur
- Compensation of € - € per visit/call (minimum € for completing all required appointments; additional compensation for optional visits)
- Aged 18-59 years
- In good health
- Not pregnant or breastfeeding (for women)
- No influenza vaccination in the past 6 months
Contact
089 4400-59850
E-mail:
Impfstudien-Tropeninstitut@med.uni-muenchen.de
Please include the keyword "Influenza" in your e-mail.